ArticleFrontiers in nutrition2024
Preparation, characterization, and anticancer effect of Capsaicin-functionalized selenium nanoparticles.
Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The anticancer effect of γ-irradiation synthesized selenium nanoparticles stabilized in β-glucan on HepG2 cell proliferationNanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Selenium nanoparticles (SeNPs) are recently emerging as promising anticancer agents because of their high bioavailability, low toxicity and remarkable anticancer activities. However, the application of SeNPs in anticancer has been limited due to instability. Herein, Capsaicin (Cap), a natural active compound found in chili peppers with favorable anticancer activity, was modified with SeNPs to prepare Cap-decorated SeNPs (Cap@SeNPs), and the antiproliferative effect and mechanism of Cap@SeNPs in HepG2 were investigated. Methods: Cap@SeNPs were prepared through a redox method and characterized using ultraviolet-visible spectroscopy and Fourier transform infrared spectroscopy. Subsequently, the inhibitory rate of Cap@SeNPs on HepG2 cells was determined by the MTT assay. Finally, the antiproliferative mechanism of Cap@SeNPs was explored through analysis of cell cycle, cell viability, reactive oxygen species levels, mitochondrial membrane potential, nuclear morphology, and caspase activity. Results: Our results revealed that stable and well-dispersed Cap@SeNPs were successfully fabricated, and the optimum mass ratio of sodium selenite to Cap was 1:2. In addition, Cap@SeNPs showed significant antiproliferative effects on HepG2 cells compared with naked SeNPs. Furthermore, Cap@SeNPs inhibited the proliferation of HepG2 cells by elevating total ROS levels, causing nuclear condensation, affecting mitochondrial membrane potential, which in turn influences caspase protease activity and induces apoptosis. Conclusion: This study developed an innovative approach to enhance the value of Cap, demonstrating that Cap@SeNPs hold promise as potential therapeutic agents for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.